NEW YORK, Aug. 15, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Neos Therapeutics, Inc. NEOS, Federated National Holding Company FNHC, FutureFuel Corp. FF, Golden Entertainment, Inc. GDEN, Intra-Cellular Therapies Inc. ITCI, and HTG Molecular Diagnostics, Inc. HTGM, including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
NEOS DOWNLOAD: http://Fundamental-Markets.com/register/?so=NEOS
FNHC DOWNLOAD: http://Fundamental-Markets.com/register/?so=FNHC
FF DOWNLOAD: http://Fundamental-Markets.com/register/?so=FF
GDEN DOWNLOAD: http://Fundamental-Markets.com/register/?so=GDEN
ITCI DOWNLOAD: http://Fundamental-Markets.com/register/?so=ITCI
HTGM DOWNLOAD: http://Fundamental-Markets.com/register/?so=HTGM
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Fundamental Markets, available for free download at the links above, examine Neos Therapeutics, Inc. NEOS, Federated National Holding Company FNHC, FutureFuel Corp. FF, Golden Entertainment, Inc. GDEN, Intra-Cellular Therapies Inc. ITCI, and HTG Molecular Diagnostics, Inc. HTGM on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed August 13th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
NEOS THERAPEUTICS, INC. (NEOS) REPORT OVERVIEW
Neos Therapeutics' Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, Neos Therapeutics reported revenue of $11.36MM vs $5.18MM (up 119.41%) and basic earnings per share -$0.52 vs -$0.82. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Neos Therapeutics reported revenue of $25.02MM vs $9.15MM (up 173.30%) and basic earnings per share -$2.68 vs -$5.19. Neos Therapeutics is expected to report earnings on November 14th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.58. The estimated EPS forecast for the next fiscal year is -$0.32 and is expected to report on March 21st, 2019.
To read the full Neos Therapeutics, Inc. (NEOS) report, download it here: http://Fundamental-Markets.com/register/?so=NEOS
-----------------------------------------
FEDERATED NATIONAL HOLDING COMPANY (FNHC) REPORT OVERVIEW
Federated National Holding's Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, Federated National Holding reported revenue of $95.74MM vs $98.16MM (down 2.46%) and basic earnings per share $0.69 vs $0.30 (up 130.00%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Federated National Holding reported revenue of $391.66MM vs $307.53MM (up 27.36%) and basic earnings per share $0.61 vs $0.07 (up 771.43%). Federated National Holding is expected to report earnings on November 5th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.42. The estimated EPS forecast for the next fiscal year is $2.65 and is expected to report on March 12th, 2019.
To read the full Federated National Holding Company (FNHC) report, download it here: http://Fundamental-Markets.com/register/?so=FNHC
-----------------------------------------
FUTUREFUEL CORP. (FF) REPORT OVERVIEW
FutureFuel's Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, FutureFuel reported revenue of $88.34MM vs $68.05MM (up 29.81%) and basic earnings per share $0.14 vs $0.02 (up 600.00%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, FutureFuel reported revenue of $275.03MM vs $253.19MM (up 8.62%) and basic earnings per share $0.54 vs $1.29 (down 58.14%). FutureFuel is expected to report earnings on November 8th, 2018. The report will be for the fiscal period ending September 30th, 2018.
To read the full FutureFuel Corp. (FF) report, download it here: http://Fundamental-Markets.com/register/?so=FF
-----------------------------------------
GOLDEN ENTERTAINMENT, INC. (GDEN) REPORT OVERVIEW
Golden Entertainment's Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, Golden Entertainment reported revenue of $216.54MM vs $109.89MM (up 97.06%) and basic earnings per share $0.13 vs $0.08 (up 62.50%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Golden Entertainment reported revenue of $509.81MM vs $403.20MM (up 26.44%) and basic earnings per share $0.09 vs $0.74 (down 87.84%). Golden Entertainment is expected to report earnings on November 14th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $0.36. The estimated EPS forecast for the next fiscal year is $2.04 and is expected to report on March 21st, 2019.
To read the full Golden Entertainment, Inc. (GDEN) report, download it here: http://Fundamental-Markets.com/register/?so=GDEN
-----------------------------------------
INTRA-CELLULAR THERAPIES INC. (ITCI) REPORT OVERVIEW
Intra-Cellular Therapies' Recent Financial Performance
For the twelve months ended December 31st, 2017 vs December 31st, 2016, Intra-Cellular Therapies reported revenue of $0.25MM vs $0.33MM (down 25.67%) and basic earnings per share -$2.12 vs -$2.69. Intra-Cellular Therapies is expected to report earnings on November 14th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.53. The estimated EPS forecast for the next fiscal year is -$3.64 and is expected to report on March 7th, 2019.
To read the full Intra-Cellular Therapies Inc. (ITCI) report, download it here: http://Fundamental-Markets.com/register/?so=ITCI
-----------------------------------------
HTG MOLECULAR DIAGNOSTICS, INC. (HTGM) REPORT OVERVIEW
HTG Molecular Diagnostics' Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, HTG Molecular Diagnostics reported revenue of $4.91MM vs $1.76MM (up 178.90%) and basic earnings per share -$0.14 vs -$0.60. For the twelve months ended December 31st, 2017 vs December 31st, 2016, HTG Molecular Diagnostics reported revenue of $14.76MM vs $5.13MM (up 187.56%) and basic earnings per share -$1.79 vs -$3.66. HTG Molecular Diagnostics is expected to report earnings on November 6th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.46. The estimated EPS forecast for the next fiscal year is -$0.52 and is expected to report on March 28th, 2019.
To read the full HTG Molecular Diagnostics, Inc. (HTGM) report, download it here: http://Fundamental-Markets.com/register/?so=HTGM
-----------------------------------------
ABOUT FUNDAMENTAL MARKETS
Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.
REGISTERED MEMBER STATUS
Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com
© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
